Literature DB >> 27084248

Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.

Takeo Sarashina1,2, Haruko Iwabuchi3, Naoyuki Miyagawa4, Masahiro Sekimizu4, Tomoko Yokosuka4, Kunio Fukuda4, Satoshi Hamanoue4, Fuminori Iwasaki4, Shoko Goto4, Masae Shiomi4, Chihaya Imai3, Hiroaki Goto4.   

Abstract

Mature B-cell acute lymphoblastic leukemia (B-ALL) is typically associated with French-American-British (FAB)-L3 morphology and MYC gene rearrangement. However, rare cases of mature B-ALL with non-L3 morphology and MLL-AF9 fusion have been reported, and such cases are characterized by a rapid and aggressive clinical course. We here report three such cases of pediatric mature B-ALL in female patients respectively aged 15 months, 4 years, and 4 months. Bone marrow smears at diagnosis showed FAB-L1 morphology in all patients. Immunophenotypically, they were positive for cluster of differentiation (CD)10, CD19, CD20 (or CD22), Human Leukocyte Antigen-DR, and surface immunoglobulin λ. No evidence of MYC rearrangement was detected in any of the cases by fluorescent in situ hybridization (FISH) analysis. However, MLL rearrangement was detected by FISH, and MLL-AF9 fusion was confirmed by reverse transcriptase-polymerase chain reaction. All patients achieved complete remission after conventional chemotherapy and subsequently underwent hematopoietic stem cell transplantation as high-risk ALL; patient 3 for infantile ALL with MLL rearrangement and the others for ALL with MLL rearrangement and hyperleukocytosis (white blood cell count at diagnosis >50 × 10(9)/L). At the latest follow-up for each case (12-98 months post-transplantation), complete remission was maintained. Moreover, we discuss the clinical, genetic, and immunophenotypic features of this rare disease.

Entities:  

Keywords:  MLL-AF9; Mature B-ALL; Non-L3 morphology; Stem cell transplantation

Mesh:

Substances:

Year:  2016        PMID: 27084248     DOI: 10.1007/s12185-016-1971-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia.

Authors:  Lawrence Tsao; Hediya Y Draoua; Ifeyinwa Osunkwo; Subhadra V Nandula; Vundavalli V S Murty; Mahesh Mansukhani; Govind Bhagat; Bachir Alobeid
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

2.  Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Shotaro Iwamoto; Takao Deguchi; Hideaki Ohta; Nobutaka Kiyokawa; Masahito Tsurusawa; Tomomi Yamada; Kozo Takase; Junichiro Fujimoto; Ryoji Hanada; Hiroki Hori; Keizo Horibe; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2011-07-30       Impact factor: 2.490

3.  Lymphoblastic Leukemia With Mature B-Cell Phenotype in Infancy.

Authors:  John L Frater; Jacqueline R Batanian; Dennis M O'Connor; Leonard E Grosso
Journal:  J Pediatr Hematol Oncol       Date:  2004-10       Impact factor: 1.289

4.  Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.

Authors:  M W J C Jansen; L Corral; V H J van der Velden; R Panzer-Grümayer; M Schrappe; A Schrauder; R Marschalek; C Meyer; M L den Boer; W J C Hop; M G Valsecchi; G Basso; A Biondi; R Pieters; J J M van Dongen
Journal:  Leukemia       Date:  2007-02-01       Impact factor: 11.528

5.  Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.

Authors:  Andishe Attarbaschi; Georg Mann; Margit König; Manuel Steiner; Sabine Strehl; Anita Schreiberhuber; Björn Schneider; Claus Meyer; Rolf Marschalek; Arndt Borkhardt; Winfried F Pickl; Thomas Lion; Helmut Gadner; Oskar A Haas; Michael N Dworzak
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

6.  The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

Authors:  Wilhelm Woessmann; Kathrin Seidemann; Georg Mann; Martin Zimmermann; Birgit Burkhardt; Ilske Oschlies; Wolf-Dieter Ludwig; Thomas Klingebiel; Norbert Graf; Bernd Gruhn; Heribert Juergens; Felix Niggli; Reza Parwaresch; Helmut Gadner; Hansjoerg Riehm; Martin Schrappe; Alfred Reiter
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

7.  Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia.

Authors:  N Blin; F Méchinaud; P Talmant; R Garand; P Boutard; N Dastugue; E A McIntyre; J L Harousseau; H Avet-Loiseau
Journal:  Leukemia       Date:  2007-11-15       Impact factor: 11.528

Review 8.  11q23 rearrangements in acute leukemia.

Authors:  J E Rubnitz; F G Behm; J R Downing
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

9.  Immunoglobulin gene rearrangements in acute lymphoblastic leukemia with the 9;11 translocation.

Authors:  A N Lorenzana; C M Rubin; M M Le Beau; J Nachman; P Connolly; U Subramanian; F L Johnson; T W McKeithan
Journal:  Genes Chromosomes Cancer       Date:  1991-01       Impact factor: 5.006

10.  Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.

Authors:  K Koh; D Tomizawa; A Moriya Saito; T Watanabe; T Miyamura; M Hirayama; Y Takahashi; A Ogawa; K Kato; K Sugita; T Sato; T Deguchi; Y Hayashi; J Takita; Y Takeshita; M Tsurusawa; K Horibe; S Mizutani; E Ishii
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

View more
  1 in total

Review 1.  Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews.

Authors:  Yinghui Cui; Min Zhou; Pinli Zou; Xin Liao; Jianwen Xiao
Journal:  Orphanet J Rare Dis       Date:  2021-07-30       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.